Presage grants MEI rights to cancer candidate voruciclib

Presage Biosciences (Seattle, Wash.) granted MEI Pharma Inc. (NASDAQ:MEIP) exclusive, worldwide rights to develop and commercialize cancer candidate voruciclib (formerly P1446A) for near-term payments of $2.9 million and up to $181 million in milestones, plus mid single-digit tiered royalties...